Kythera Biopharmaceuticals and Intendis, Inc. Announce Initiation of European Phase III Clinical Development Program to Evaluate ATX-101 for Reduction of Submental Fat

(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) and Intendis, Bayer HealthCare’s dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).